Market Place
Sourcing Support
All News #Library
FDA Issues Form 483 to Hetero Labs
26 Sep 2025 //
FDA
FDA Issues Form 483 to Hetero Labs Unit-IX
26 Sep 2025 //
FDA
Enforcement Report - Week of May 17, 2023
17 May 2023 //
FDA
Enforcement Report - Week of April 19, 2023
19 Apr 2023 //
FDA
Enforcement Report - Week of September 2, 2020
02 Sep 2020 //
FDA
Legacy Pharmaceutical Packaging Issues Recall of Losartan Potassium Tablets
19 Mar 2019 //
FDA
Hetero Labs Ltd. Unit I on Health Canada Inspection List
20 Feb 2019 //
HEALTH CANADA
Torrent Pharmaceuticals Expands Recall of Losartan Potassium Tablets
04 Jan 2019 //
FDA
Torrent Pharmaceuticals Recalls Losartan Potassium Tablets
21 Dec 2018 //
FDA
Valsartan products under recall - Updated November 27, 2018
28 Nov 2018 //
FDA
Hetero Labs Ltd. Unit I on Health Canada Inspection List
18 Oct 2018 //
HEALTH CANADA
Enforcement Report - Week of October 3, 2018
03 Oct 2018 //
FDA
Enforcement Report - Week of August 29, 2018
29 Aug 2018 //
FDA
FDA Issues Form 483 to Hetero Drugs Ltd. Unit 1
18 Jul 2018 //
FDA
Enforcement Report - Week of March 21, 2018
21 Mar 2018 //
FDA
Enforcement Report - Week of February 14, 2018
14 Feb 2018 //
FDA
Enforcement Report - Week of January 24, 2018
24 Jan 2018 //
FDA
Hetero Labs Limited on Health Canada Inspection List
28 Sep 2017 //
HEALTH CANADA
Hetero Labs Limited Unit V Receives FDA Warning Letter
30 Aug 2017 //
FDA
Enforcement Report - Week of June 14, 2017
14 Jun 2017 //
FDA
Enforcement Report - Week of April 5, 2017
05 Apr 2017 //
FDA
FDA Issues Form 483 to Hetero Labs Limited
13 Jan 2017 //
FDA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.